Kenneth Reay Code - 14 Nov 2025 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Reporting relationship: Chief Science Officer, Director
Issuer ticker: BLGO
Reported as of: 14 Nov 2025
Net transaction value: +$50,201
SEC form: 4
Accepted by SEC: 17 Nov 2025, 20:12:54 UTC
Prior SEC filing: 16 Jul 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ John R. Browning, attorney-in-fact

Key filing fact

Kenneth Reay Code filed Form 4 for BIOLARGO, INC. (BLGO) on 17 Nov 2025.

Key facts

This page summarizes Kenneth Reay Code's Form 4 filing for BIOLARGO, INC. (BLGO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Nov 2025, 20:12.

Change

Previous filing in this sequence was filed on 16 Jul 2025.
Current net transaction value: +$50,201.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001370684 Primary reporting owner

CODE KENNETH REAY

Relationship: Chief Science Officer, Director
Address: 14921 CHESTNUT ST., WESTMINSTER
Signature: /s/ John R. Browning, attorney-in-fact
Signature date: 17 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLGO transaction

Common Stock

Award

Transaction value: $50,201
Shares: +313,754
Change %: +1.2%
Price: $0.1600
Shares after: 25,751,505
Date: 14 Nov 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares issued are subject to a Lock-Up Agreement dated as of the issuance date whereby shares are locked-up and restricted from sale until the Issuer reports gross revenue of at least $40 million on a consolidated basis for any reported period (e.g, quarter or annual), or the Issuer's market capitalization exceeds $300 million, or there is a "change in control" in the Issuer.

Footnote F2

Shares received from Issuer in exchange for a reduction in amounts owed by Issuer to Reporting Person for salary and unreimbursed business expenses (equal to the product of the number of shares and acquisition price per share).

Footnote F3

Aggregate total shares includes 22,139,012 shares owned indirectly by Reporting Person through a wholly owned corporation.